Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track ELOX with free AI briefings, catalyst countdowns, and dilution alerts.

ELOX · Eloxx Pharmaceuticals, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$62M Cash on Hand
36.3mo Cash Runway
Follow ELOX by email Get an email when ELOX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ELOX, unsubscribe in one click. Privacy

📣 What ELOX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
ELX-02 Alport Syndrome Phase 2 · NCT05448755 Completed
Exaluren Alport Syndrome, X-Linked Phase 2 · NCT07523581 Recruiting

Also used in these trials (approved or third-party drugs, not ELOX's own candidates): Ivacaftor.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

ELOX holds $62M in cash and short-term investments (as of Jun 30, 2026) and burns about $5.1M/quarter from operations, an estimated runway of 36.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 8 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ELOX files for a raise →

👥 Who Owns ELOX

Insiders 6.4% Other 5%+ holders 19.8% Institutions (23 holders) 73.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Domicilium Capital Partners LLC Institution (13G, 5%+) 854,973 20.92% 2026-06-05
Coastlands Capital LP Institution (13G, 5%+) 422,716 10.34% 2026-09-30
Srinivas Akkaraju 5%+ holder (13G) 403,586 9.88% 2026-06-10
EcoR1 Capital, LLC Institution (13G, 5%+) 403,586 9.88% 2026-06-09
Raymond Debbane 5%+ holder (13G) 403,586 9.88% 2026-06-09
Stonepine Capital Management, LLC Institution (13G, 5%+) 403,228 9.87% 2026-06-09
Nantahala Capital Management, LLC Institution (13G, 5%+) 400,000 9.79% 2026-06-30
Aberdeen Group plc Institution (13G, 5%+) 400,000 9.79% 2026-06-30
Sumit Aggarwal
President and CEO, Director · +3.69M options
Insider 199,930 4.89% 2025-01-24
Lindsay Androski
Director · +3,750 options
Insider 15,750 0.39% 2025-01-24
Alan Edmund Walts
Director · +406,145 options
Insider 15,567 0.38% 2025-09-19
Steven D Rubin
Director · +185,747 options
Insider 14,625 0.36% 2025-09-19

Share count 4,086,705 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full ELOX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ELOX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.